Alexa Fluor® 488 anti-human CD326 (EpCAM) Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

DU.4475 breast carcinoma

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 488 under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested
SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.

Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses

Excitation Laser

Blue Laser (488 nm)

Application Notes

Additional reported applications (for the revelant formats) include: immunofluorescence, immunohistochemistry³, and spatial biology (IBEX)^4,5.

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Lammers R, et al. 2002. Exp. Hematol. 30:537.
2. Schultz LD, et al. 2010. P. Natl. Acad. Sci. USA 107:13022. PubMed
3. Human Protein Atlas http://www.proteinatlas.org/ENSG00000119888/antibody (IHC)
4. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Zabala M, et al. 2020. Cell Stem Cell. 27(2):284-299.e8. PubMed
2. Qin XY, et al. 2023. Cell Death Dis. 14:358. PubMed
3. Yu L, et al. 2020. Cell Stem Cell. 28(3):550-567.e12. PubMed
4. Carraro G, et al. 2021. Nat Med. 27:806. PubMed
5. Howden SE, et al. 2020. Cell Stem Cell. 28(4):671-684.e6. PubMed
6. Pal D et al. 2017. eLife. 6 pii: e21615. PubMed
7. Palkowitz AL, et al. 2021. Adv Healthc Mater. 10:e2100132. PubMed
8. Pyo DH, et al. 2020. Cancer Biol Ther. 495:21. PubMed
9. Morsing M, et al. 2020. Breast Cancer Res. 0.9875. PubMed
10. Cai X, et al. 2014. PLoS One. 9:108942. PubMed
11. Calandrini C, et al. 2020. Nat Commun. 11:1310. PubMed
12. Gerdur ísberg ó, et al. 2019. Sci Rep. 9:14843. PubMed
13. Inde Z, et al. 2021. Sci Adv. 7:. PubMed
14. Sullivan NT, et al. 2022. STAR Protoc. 3:101367. PubMed
15. Hu H et al. 2018. Cell. 175(6):1591-1606 . PubMed
16. Chen D, et al. 2019. Cell Rep. 29:4568. PubMed
17. Safaric Tepes P, et al. 2021. Elife. 10: . PubMed
18. Cardenas JJ, et al. 2020. Methods Enzymol. 415:631. PubMed
19. Gell JJ, et al. 2018. Stem Cell Res. 27:46. PubMed
20. Noort V, et al. 2014. Cancer Res. 74:5690. PubMed
21. Morris K, et al. 2014. PLoS One. 9:98656. PubMed
22. Hong HK, et al. 2019. Oncol Rep. 42:2029. PubMed
23. Hancock GV, et al. 2021. Stem Cell Res. 55:102493. PubMed
24. Chen D et al. 2018. Cell reports. 25(13):3591-3602 . PubMed
25. Vanslambrouck JM, et al. 2019. J Am Soc Nephrol. 30:1811. PubMed
26. Chen D, et al. 2017. Biol Reprod. 97:850. PubMed
27. Staudte S, et al. 2022. Cancers (Basel). 14:. PubMed
28. Vanslambrouck JM, et al. 2022. Nat Commun. 13:5943. PubMed
29. Cai X, et al. 2017. Neoplasia. 10.1016/j.neo.2017.03.005. PubMed
30. Koyama M et al. 2019. Immunity. 51(5):885-898 . PubMed
31. Horwitz K, et al. 2008. Proc Natl Acad Sci U S A. 105:5774. PubMed
32. Chitiashvili T, et al. 2020. Nat Cell Biol. 22:1436. PubMed
33. Sandlin CW, et al. 2022. PLoS One. 17:e0274091. PubMed
34. Pandolfi EC, et al. 2022. Cell Rep Med. 3:100782. PubMed
35. Mourcin F, et al. 2021. Immunity. . PubMed
36. Catenacci D, et al. 2015. Gastroenterology. 149: 1794-1803.e4. PubMed
37. Forbes TA, et al. 2018. Am J Hum Genet. 102:816. PubMed
38. Jeong HO, et al. 2022. iScience. 25:105358. PubMed

RRID

AB_756083 (BioLegend Cat. No. 324209)
AB_756083 (BioLegend Cat. No. 324210)

Antigen Details

Structure

Type I transmembrane protein, contains six disulfide bridges, one THYRO domain, approximate molecular weight 40 kD.

Distribution

Highly expressed in bone marrow, colon, lung, and most normal epithelial cells. Also highly expressed on carcinomas of gastrointestinal origin. Expressed during early erythrogenesis.

Function

Homotypic calcium-independent cell adhesion. CD326 is believed to be involved in carcinogenesis by its ability to induce genes involved in cellular metabolism and proliferation.

Modification

Glycosylated.

Cell Type

Embryonic Stem Cells, Epithelial cells

Biology Area

Cell Biology, Immunology, Stem Cells

Molecular Family

Adhesion Molecules, CD Molecules

Antigen References

1. Strnad J, et al. 1989. Cancer Res. 49:314.
2. Munz M, et al. 2004. Oncogene 23:5748.
3. Rao CG, et al. 2005. Int. J. Oncol. 27:49.

Gene ID

4072 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

CD326

Specificity Alt (DOES NOT SHOW ON TDS):

CD326

App Abbreviation (DOES NOT SHOW ON TDS):

FC,SB

UniProt

View information about CD326 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

Certificate of Analysis